Page 320 - Read Online

Chen et al. Hepatoma Res 2018;4:29 I http://dx.doi.org/10.20517/2394-5079.2018.18 Page 11 of 15

5. Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future
perspectives. Jpn J Clin Oncol 2018;48:103-14.
6. Stroffolini T, Sagnelli E, Andriulli A, Colloredo G, Furlan C, Gaeta G, Morisco F, Pirisi M, Rosina F, Sagnelli C, Smedile A, Almasio
P. Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis. PLoS One
2017;12:e0185710.
7. Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, Hayakawa Y, Kinoshita H, Yamakado M, Kato N, Shiina S, Omata
M. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J
Cancer 2009;125:2264-9.
8. von Mehren M, Rankin C, Goldblum J, Demetri G, Bramwell V, Ryan C, Borden E. Phase 2 Southwest Oncology Group-directed
intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 2012;118:770-6.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
10. Nakagawa H, Maeda S. Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol
2012;18:4071-81.
11. Inoue J, Ninomiya M, Shimosegawa T, McNiven M. Cellular membrane trafficking machineries utilized by the hepatitis viruses.
Hepatology 2018; doi: 10.1002/hep.29785.
12. Leung N. HBV and liver cancer. Med J Malaysia 2005;60 Suppl B:63-6.
13. Lu J, Chuang L, Yang W, Tai T, Lai M, Chen P, Kao J, Lee C, Lee H. Adiponectin levels among patients with chronic hepatitis B and C
infections and in response to IFN-alpha therapy. Liver Int 2005;25:752-9.
14. Di Fazio I, Motta M, Musumeci S, Neri S, Pistone G, Malaguarnera M. Efficacy of human recombinant erythropoietin plus IFN-alpha
in patients affected by chronic hepatitis C. J Interferon Cytokine Res 2004;24:594-9.
15. Nan J, Xing Y, Hu B, Tang J, Dong H, He Y, Ruan D, Ye Q, Cai J, Ma X, Chen J, Cai X, Lin Z, Wu X, Li X. Endoplasmic reticulum
stress induced LOX-1+ CD15+ polymorphonuclear myeloid-derived suppressor cells in hepatocellular carcinoma. Immunology
2018;154:144-55.
16. Liu M, Jin L, Sun S, Liu P, Feng X, Cheng Z, Liu W, Guan K, Shi Y, Yuan H, Xiong Y. Metabolic reprogramming by PCK1
promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma. Oncogene
2018;37:1637-53.
17. Rabachini T, Fernandez-Marrero Y, Montani M, Loforese G, Sladky V, He Z, Bachmann D, Wicki S, Villunger A, Stroka D, Kaufmann T.
BOK promotes chemical-induced hepatocarcinogenesis in mice. Cell Death Differ 2018;25:706-18.
18. Wang B, Fu J, Yu T, Xu A, Qin W, Yang Z, Chen Y, Wang H. Contradictory effects of mitochondria- and non-mitochondria-targeted
antioxidants on hepatocarcinogenesis by altering DNA repair in mice. Hepatology 2017; doi: 10.1002/hep.29518.
19. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol
2006;72:1605-21.
20. Guo Y, Zhao Q, Cao L, Zhao B. Hepatoprotective effect of Gan Kang Yuan against chronic liver injury induced by alcohol. J
Ethnopharmacol 2017;208:1-7.
21. Hamilton DL, Vest TK, Brown BS, Shah AN, Menguy RB, Chey WY. Liver injury with alcoholiclike hyalin after gastroplasty for
morbid obesity. Gastroenterology 1983;85:722-6.
22. Kaplan JM, Nowell M, Lahni P, Shen H, Shanmukhappa SK, Zingarelli B. Obesity enhances sepsis-induced liver inflammation and
injury in mice. Obesity (Silver Spring) 2016;24:1480-8.
23. Kirpich I, McClain C. More alcohol, more liver injury: not always true. Alcohol Alcohol 2017;52:627-8.
24. Marin V, Poulsen K, Odena G, McMullen MR, Altamirano J, Sancho-Bru P, Tiribelli C, Caballeria J, Rosso N, Bataller R, Nagy LE.
Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients. J Hepatol
2017;67:1018-25.
25. Williams JA, Manley S, Ding WX. New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases.
World J Gastroenterol 2014;20:12908-33.
26. Liu Z, Ning F, Wang H, Chen D, Cai Y, Sheng H, Lash G, Liu L, Du J. Epidermal growth factor and tumor necrosis factor α
cooperatively promote the motility of hepatocellular carcinoma cell lines via synergistic induction of fibronectin by NF-κB/p65.
Biochim Biophys Acta 2017;1861:2568-82.
27. Huang B, Lin C, Wang C, Kao S. Upregulation of heat shock protein 70 and the differential protein expression induced by tumor
necrosis factor-alpha enhances migration and inhibits apoptosis of hepatocellular carcinoma cell HepG2. Int J Med Sci 2017;14:284-93.
28. Zhang Q, Wang H, Mao C, Sun M, Dominah G, Chen L, Zhuang Z. Fatty acid oxidation contributes to IL-1β secretion in M2
macrophages and promotes macrophage-mediated tumor cell migration. Mol Immunol 2017;94:27-35.
29. Zhang J, Zhang Q, Lou Y, Fu Q, Chen Q, Wei T, Yang J, Tang J, Wang J, Chen Y, Zhang X, Zhang J, Bai X, Liang T. Hypoxia-
inducible factor-1α/interleukin-1β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-
inflammatory microenvironment. Hepatology 2018;67:1872-89.
30. Wadkin J, Patten D, Kamarajah S, Shepherd E, Novitskaya V, Berditchevski F, Adams D, Weston C, Shetty S. CD151 supports VCAM-
1-mediated lymphocyte adhesion to liver endothelium and is upregulated in chronic liver disease and hepatocellular carcinoma. Am J
Physiol Gastrointest Liver Physiol 2017;313:G138-49.
31. Castelli G, Pelosi E, Testa U. Liver cancer: molecular characterization, clonal evolution and cancer stem cells. Cancers (Basel)
2017;9:E127.
32. Guo W, Liu S, Cheng Y, Lu L, Shi J, Xu G, Li N, Cheng K, Wu M, Cheng S, Liu S. ICAM-1-related noncoding RNA in cancer stem
cells maintains ICAM-1 expression in hepatocellular carcinoma. Clin Cancer Res 2016;22:2041-50.